4053-35-4

Usage

Uses

Used in Pharmaceutical Industry:
7-methyl-2-quinolone is used as an active pharmaceutical ingredient for its potential antibacterial, antiviral, and anti-inflammatory properties, contributing to the development of new drugs and therapies.
Used in Dye Industry:
7-methyl-2-quinolone is used as a chemical intermediate in the production of dyes, owing to its aromatic structure and reactivity.
Used in Organic Chemicals Industry:
7-methyl-2-quinolone is utilized as a building block in the synthesis of other organic chemicals, taking advantage of its versatile chemical properties.
Used in Chemical Research:
7-methyl-2-quinolone serves as a subject of study for its potential applications in chemical research, including the development of new synthetic methods and the exploration of its reactivity and properties.
Used in Biological Research:
7-methyl-2-quinolone is used in biological research to investigate its role as a signaling molecule in bacteria, which can provide insights into bacterial communication and the development of new antimicrobial strategies.

InChI:InChI=1/C10H9NO/c1-7-2-3-8-4-5-10(12)11-9(8)6-7/h2-6H,1H3,(H,11,12)

Upstream product

• 4053-43-4 7-methylquinoline N-oxide 
• 108-44-1 1-amino-3-methylbenzene 
• 140-88-5 ethyl acrylate 
• 612-60-2 7-methylquinoline 
• 591-24-2 3-Methylcyclohexanone 
• 141-32-2 acrylic acid n-butyl ester 
• 1415586-02-5 C₉H₁₅NO 
• 57830-64-5 3′-methylcinnamanilide 

Downstream Products

• 19352-59-1 3,4-dihydro-7-methyl-2(1H)-quinolinone 

Relevant academic research and scientific papers

PRMT5 INHIBITOR COMPOUNDS

A series of PRMT5 inhibitor compounds are described. The compounds are useful as PRMT5 inhibitor compounds and in the treatment of PRMT5 mediated diseases, disorders, and symptoms thereof.

Palladium-catalyzed synthesis of quinolin-2(1: H)-ones: the unexpected reactivity of azodicarboxylate

Quinolin-2(1H)-one is a useful structure unit present in a wide range of natural products and pharmaceuticals. A Pd(ii)-catalyzed synthesis of quinolin-2(1H)-ones from quinoline N-oxides was developed with azodicarboxylates which act as both the activating agent and oxidant. The reaction proceeded under mild conditions and no protection against air and moisture was needed.

Enantioselective Intermolecular [2 + 2] Photocycloaddition Reactions of 2(1H)-Quinolones Induced by Visible Light Irradiation

In the presence of a chiral thioxanthone catalyst (10 mol %) the title compounds underwent a clean intermolecular [2 + 2] photocycloaddition with electron-deficient olefins at λ = 419 nm. The reactions not only proceeded with excellent regio- and diastereoselectivity but also delivered the respective cyclobutane products with significant enantiomeric excess (up to 95% ee). Key to the success of the reactions is a two-point hydrogen bonding between quinolone and catalyst enabling efficient energy transfer and high enantioface differentiation. Preliminary work indicated that solar irradiation can be used for this process and that the substrate scope can be further expanded to isoquinolones.

2-AMINOQUINOLINE-BASED COMPOUNDS FOR POTENT AND SELECTIVE NEURONAL NITRIC OXIDE SYNTHASE INHIBITION

Various 2-aminoquinoline compounds as can be used, in vivo or in vitro, for selective inhibition of neuronal nitric oxide synthase.

2-aminoquinoline-based compounds for potent and selective neuronal nitric oxide synthase inhibition

Various 2-aminoquinoline compounds as can be used, in vivo or in vitro, for selective inhibition of neuronal nitric oxide synthase.

Practical route to 2-quinolinones via a Pd-catalyzed C-H bond activation/C-C bond formation/cyclization cascade reaction

Quinolinone derivatives were constructed via a Pd-catalyzed C-H bond activation/C-C bond formation/cyclization cascade process with simple anilines as the substrates. This finding provides a practical procedure for the synthesis of quinolinone-containing alkaloids and drug molecules. The utility of this method was demonstrated by a formal synthesis of Tipifarnib.

Simplified 2-aminoquinoline-based scaffold for potent and selective neuronal nitric oxide synthase inhibition

Since high levels of nitric oxide (NO) are implicated in neurodegenerative disorders, inhibition of the neuronal isoform of nitric oxide synthase (nNOS) and reduction of NO levels are therapeutically desirable. Nonetheless, many nNOS inhibitors mimic l-arginine and are poorly bioavailable. 2-Aminoquinoline-based scaffolds were designed with the hope that they could (a) mimic aminopyridines as potent, isoform-selective arginine isosteres and (b) possess chemical properties more conducive to oral bioavailability and CNS penetration. A series of these compounds was synthesized and assayed against purified nNOS enzymes, endothelial NOS (eNOS), and inducible NOS (iNOS). Several compounds built on a 7-substituted 2-aminoquinoline core are potent and isoform-selective; X-ray crystallography indicates that aminoquinolines exert inhibitory effects by mimicking substrate interactions with the conserved active site glutamate residue. The most potent and selective compounds, 7 and 15, were tested in a Caco-2 assay and showed good permeability and low efflux, suggesting high potential for oral bioavailability.

A Pd-Catalyzed one-pot dehydrogenative aromatization and ortho-functionalization sequence of N-acetyl enamides

The one-pot dehydrogenation and ortho-functionalization sequence provides access to highly functionalized arylamine-containing derivatives from readily accessible cyclic N-acetyl enamides. The Royal Society of Chemistry 2014.

DIHYDRONAPHTHYRIDINYL AND RELATED COMPOUNDS FOR USE IN TREATING OPHTHALMOLOGICAL DISORDERS

The invention provides methods of using dihydronaphthyridinyl and related compounds to treat ophthalmological disorders, such as, wet age-related macular degeneration, diabetic retinopathy, and high myopia. Pharmaceutical compositions and methods of synthesizing the dihydronaphthyridinyl and related compounds are provided

Carboxamide Compounds and Their Use

Chemokine receptor antagonists, in particular, compounds of Formula (I-A) that act as antagonists of the chemokine CCR2 receptor, including pharmaceutical compositions and uses thereof to treat or prevent diseases associated with monocyte accumulation, lymphocyte accumulation or leukocyte accumulation are described herein.